Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.
Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. · 2017
Read Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. by Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5296331.txt.
Description
Vivek Kumar, Neha Chaudhary, Mohit Garg, Charalampos S. Floudas, Parita Soni, and Abhinav B. Chandra reviewed the side effects of immune checkpoint inhibitors in Frontiers in Pharmacology in 2017. These cancer drugs release the brakes on T cells by blocking CTLA-4 or the PD-1 pathway, and their approved uses keep growing. Unleashed immunity, though, attacks healthy tissue too, producing immune-related adverse events.
The common sites are skin, gut, and hormone glands, but rarer attacks on nerves, blood, and kidneys are now documented, and safety data are accumulating for patients who already have autoimmune disease. Caught early, most events reverse fully; only the severest grades need treatment paused and immune suppression with steroids or infliximab. The review lays out recognition and management algorithms for the main drug families and notes the research frontier: preventing these toxicities and finding markers that predict who will suffer them.
Catalog record
| CREATOR | Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |